Protocol Ledger

NCT05178862 · Phase III · TERMINATED

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Interventional Phase III clinical trial protocol NCT05178862 sponsored by Scynexis in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-08-03 Enrollment: 68 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05178862
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)68 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05178862
Protocol FieldVerified Registry Value
NCT IdentifierNCT05178862
Consolidated Lead SponsorScynexis
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment68 participants (ACTUAL)
Registered Start Date2022-08-03
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI